Sequential Angiogenic Blockade for the Treatment of Recurrent Mullerian Malignancies

Exclusion Criteria

• •Current, recent (within 4 weeks of the first study infusion), or planned participation in an experimental drug study other than a Genentech-sponsored bevacizumab cancer study
• •Active malignancy, other than superficial basal cell and superficial squamous (skin) cell, or carcinoma in situ of the cervix within last five years
• •Uncontrolled diarrhea
• •Prior history of hypertensive crisis or hypertensive encephalopathy
• •NYHA Grade II or greater congestive heart failure
• •History of myocardial infarction or unstable angina within 6 months prior to Day 1
• •History of stroke or transient ischemic attack within 6 months prior to day 1
• •Known CNS disease, except for treated brain metastasis
• •Treated brain metastases are defined as having no evidence of progression or hemorrhage after treatment and no ongoing requirement for dexamethasone, as ascertained by clinical examination and brain imaging (MRI or CT) during the screening period. Anticonvulsants (stable dose) are allowed. Treatment for brain metastases may include whole brain radiotherapy (WBRT), radiosurgery (RS: Gamma Knife, LINAC, or equivalent) or a combination as deemed appropriate by the treating physician. Patients with CNS metastases treated by neurosurgical resection or brain biopsy performed within 3 months prior to day 1 will be excluded.
• •Significant vascular disease within 6 months prior to day 1
• •History of hemoptysis within 1 month prior to day 1
• •Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
• •Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to day 1 or anticipation of need for major surgical procedure during the course of the study
• •Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to Day 1
• •History of abdominal fistula or gastrointestinal perforation within 6 months prior to Day 1
• •Serious, non-healing wound, active ulcer, or untreated bone fracture
• •Proteinuria as demonstrated by a UPC ratio of 1.0 or greater at screening
• •Known hypersensitivity to any component of bevacizumab
• •Pregnancy (positive pregnancy test) or lactation. Use of effective means of contraception (men and women) in subjects of child-bearing potential